22nd week of 2013 patent applcation highlights part 37 |
Patent application number | Title | Published |
20130136720 | METHODS OF USING FUT2 GENETIC VARIANTS TO DIAGNOSE CROHN'S DISEASE - The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the FUT2 genetic locus. | 2013-05-30 |
20130136721 | Compositions and Methods of Generating a Differentiated Mesodermal Cell - The invention features a culture system, culture system components and culture methods that are useful for the rapid and reliable generation of differentiated mesodermal cells, including cardiac myocytes, from stem cells, such as human embryonic stem cells and human induced pluripotent stem cells differentiated mesodermal cells, including differentiated cardiac myocytes. | 2013-05-30 |
20130136722 | Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts - This invention provides methods and compositions of hematopoietic progenitor cells and hematopoietic stem cells, particularly methods for expanding populations of these cells types from biological sources. | 2013-05-30 |
20130136723 | CONNECTIVE TISSUE REPAIR - The invention concerns a homogenous population of human stem cells isolated from the full depth of human cartilage tissue and/or isolated from aged human cartilage; and uses thereof. | 2013-05-30 |
20130136724 | PIG FEED, AND METHOD FOR FEEDING SAME - An object of the present invention is to provide a method for improving a farrowing rate of sows or improving growth and productivity of postnatal piglets, and a feed used in the method. The present invention relates to a method for improving a farrowing rate of a sow or improving growth and productivity of postnatal piglets, the method comprising administering coenzyme Q to a swine. | 2013-05-30 |
20130136725 | COMPOSITIONS FOR SYSTEMIC TREATMENT OF PATHOLOGICAL CONDITIONS RESULTING FROM OXIDATIVE STRESS AND/OR REDOX IMBALANCE - Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compounds and/or thionite compounds and/or thionate compounds and/or any chemical species capable of providing to a subject in need thereof a sulfide compound, thiosulfate compound, thionite compound, or thionate compound. The unique compositions of this invention contain one or more “active sulfur substances” in combination with each other or with other therapeutic agents. The invention also encompasses the varying modes of administration of the therapeutic substances. In particular, a novel method of combining active ingredient with wet cellulose is provided, which allows the wet cellulose to function as an enteric carrier. | 2013-05-30 |
20130136726 | METHOD FOR DETECTION OF PREDISPOSITION TO ATHEROSCLEROSIS, CORONARY HEART DISEASE AND RELATED CONDITIONS - Heteroplasmy mitochondrial DNA (mtDNA) markers and haplotypes of susceptibility or predisposition to atherosclerosis, coronary heart disease (CHD) and subdiagnosis of atherosclerosis and CHD and related medical conditions are disclosed. The biomarkers may be selected from the following heteroplasmy makers: 652lns/del G; A1555G; C3256T; T3336C; G12315A; G13513A; G14459A; G14846A; G15059A. Methods and kits for diagnosis, subdiagnosis, and prediction of clinical course and efficacy of treatments for CHD, atherosclerosis and related phenotypes using heteroplasmy in the risk genes and loci and other related biomarkers are thus provided. Novel methods for prevention and treatment of atherosclerosis, CHD and related conditions based on the disclosed CHD genes, loci, polypeptides and related pathways are also provided. | 2013-05-30 |
20130136727 | Angiogenin and Variants Thereof for Treatment of Neurodegenerative Diseases - Methods and compositions for treating neurodegenerative disorders using angiogenin and/or angiogenin variants are provided. | 2013-05-30 |
20130136728 | ANTI-COCAINE COMPOSITIONS AND TREATMENT - Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides. | 2013-05-30 |
20130136729 | COMPOSITIONS AND METHODS FOR TARGETING AND TREATING DISEASES AND INJURIES USING ADENO-ASSOCIATED VIRUS VECTORS - The present application discloses compositions and methods useful for targeting and treating injured or diseased muscle, including cardiac and skeletal muscle. Disclosed herein are adenoviral vectors modified to contain enhancers, promoters, and genes to target muscle with high efficiency and to induce tissue specific gene expression of transgenes. | 2013-05-30 |
20130136730 | METHODS AND MATERIALS FOR REDUCING BIOFILMS - This document provides methods and materials related to reducing biofilms. For example, enzymes (e.g., glycosyl hydrolases), nucleic acid molecules encoding enzymes, host cells containing nucleic acid encoding enzymes, and methods for using enzymes to reduce biofilms and infections associated with biofilms are provided. | 2013-05-30 |
20130136731 | Protein Fusion Constructs Possessing Thrombolytic and Anticoagulant Properties - The present invention discloses novel hybrid proteins that have both plasminogen activator and anti-thrombotic properties, including clot specific action, that renders these as highly advantageous for the treatment of circulatory disorders involving fibrin clot formation due to underlying tissue damage in the blood vessels leading to myocardial infarction, strokes etc. Also disclosed are new proteins, and methods of obtaining the same, that help to dissolve blood clots by activating plasminogen in a plasmin or thrombin dependent manner and also inhibit both the activity and generation of thrombin through the intrinsic pathway of blood coagulation. | 2013-05-30 |
20130136732 | ADAMTS13-CONTAINING COMPOSITIONS HAVING THROMBOLYTIC ACTIVITY - This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof. | 2013-05-30 |
20130136733 | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative - The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein. | 2013-05-30 |
20130136734 | ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND RELATED THERAPIES - Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein. | 2013-05-30 |
20130136735 | HUMANIZED ANTIBODIES TO iNKT - Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided. | 2013-05-30 |
20130136736 | Single Domain VHH Antibodies Against Von Willebrand Factor - The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes. | 2013-05-30 |
20130136737 | Uses of NOGO-A Inhibitors and Related Methods - The present invention is directed to Nogo-A antagonists useful for the control of blood glucose or blood insulin levels in a subject and related use and formulation thereof. In particular, the invention is directed to Nogo-A antagonists useful for the prevention, repression or treatment insulin secretion deficiency and related methods and pharmaceutical formulations. In particular, the invention relates to Nogo-A antagonists useful in the treatment of diabetes mellitus. | 2013-05-30 |
20130136738 | Methods of Treating Glucose Metabolism Disorders - Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided. | 2013-05-30 |
20130136739 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS - Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin. | 2013-05-30 |
20130136740 | METHODS OF TREATING CANCER - Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. | 2013-05-30 |
20130136741 | Novel Enhanced Selectin Antagonists - Recombinant proteins comprised of multiple selectin binding domains derived from the glycopeptide PSGL-1, in a novel tandem configuration, are disclosed, including their fusions with immunoglobulins and/or other polypeptides. Polynucleotides encoding such proteins, compositions and kits containing such proteins, and methods of using such proteins are also disclosed. | 2013-05-30 |
20130136742 | PEPTIDE HAVING CELL MEMBRANE PENETRATING ACTIVITY - Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex, and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance. | 2013-05-30 |
20130136743 | NOVEL MUTATED HUMANIZED 12G4 ANTIBODIES AND THE FRAGMENTS THEREOF AGAINST THE HUMAN ANTI-MULLERIAN HORMONE RECEPTOR TYPE II - Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor. | 2013-05-30 |
20130136744 | PULMONARY ADMINISTRATION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND CONSTRUCTS THEREOF - In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. | 2013-05-30 |
20130136745 | SOLUBLE ENDOGLIN AND USES THEREOF - The invention provides isolated soluble endoglin polypeptides, nucleic acids encoding soluble endoglin polypeptides, antibodies that specifically bind soluble endoglin polypeptides, and kits containing these materials. The invention also provides methods for treating or decreasing the likelihood of developing a soluble endoglin-mediated disorder in a subject requiring the administration of an agent capable of reducing the expression or biological activity of a soluble endoglin polypeptide and methods for treating or decreasing the likelihood of developing a soluble endoglin-preventive disorder in a subject requiring the administration of a soluble endoglin polypeptide or a nucleic acid encoding the soluble endoglin polypeptide. The invention further provides methods for the diagnosis of a soluble endoglin-mediated disorder or a soluble endoglin-preventive disorder and methods for identifying a compound to treat a soluble endoglin-mediated or a soluble endoglin-preventive disorder. | 2013-05-30 |
20130136746 | COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SpA) ANTIBODIES AS AN ENHANCER OF IMMUNE RESPONSE - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2013-05-30 |
20130136747 | ANTI-AMYLOID BETA ANTIBODIES AND THEIR USE - The present invention relates to antibody molecules capable of specifically recognizing two regions of the β-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention. | 2013-05-30 |
20130136748 | BIOLOGICAL MATERIALS RELATED TO HER3 - The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively). The disclosure also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as “nucleic acids of the invention” or “nucleotide sequences of the invention”); to methods for 10 preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein. | 2013-05-30 |
20130136749 | Human CTLA-4 Antibodies And Their Uses - The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies. | 2013-05-30 |
20130136750 | ANTIBODIES WHICH BIND FACTOR VIII - The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the C1 domain of Factor VIII, which is a partially inhibitory antibody of Factor VIII. | 2013-05-30 |
20130136751 | Methods, Compositions and Kits Relating to Chitnases and Chitnase-Like Molecules and Inflammation Disease - The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease. | 2013-05-30 |
20130136752 | Ophthalmic Formulations - The present disclosure provides novel ophthalmic formulations for ocular administration comprising a pharmaceutically effective amount of a combretastatin, from 60% to 95% w/w pre-gelatinized starch, from 1% to 10% w/w hydrophilic matrix forming polymer, and from 0.2% to 5% lubricant. | 2013-05-30 |
20130136753 | PAXILLIN AS A THERAPEUTIC OR DIAGNOSTIC MARKER FOR CANCER - The present invention relates to methods for assessing the aggressiveness or proliferative activity of a cancer that is capable of both androgen-dependent and steroid-independent growth and proliferation; as well as methods and therapeutic agents for the treatment of such cancers including, among others, prostate cancers, testicular cancers, breast cancers, endometrial cancers, uterine cancers, and ovarian cancers. | 2013-05-30 |
20130136754 | REGULATORY B CELLS AND THEIR USES - The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed. | 2013-05-30 |
20130136755 | MLK4 GENE, A NEW DIAGNOSTIC AND PROGNOSTIC MARKER IN CANCERS - An in vitro diagnostic method for determining invasive potential of cancer comprising measuring MLK4 gene expression in a cancer cell sample, wherein MLK4 gene overexpression is indicative of an invasive cancer, preferably a colorectal, bladder, breast, gastric, melanoma, lung, ovary or GMB cancer. | 2013-05-30 |
20130136756 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS - Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer. | 2013-05-30 |
20130136757 | METHODS OF TREATING CANCER USING A COMBINATION OF AN IMMUNOMODULATORY COMPOUND AND AN ARTEMISININ OR A DERIVATIVE THEREOF - Provided herein are methods for treating cancers by administering immunomodulatory compounds in combination with artemisinin or a derivative thereof. In particular, methods for treating cancers by administering lenalidomide in combination with artemisinin or a derivative thereof are provided. | 2013-05-30 |
20130136758 | Immunostimulating Polyphosphazene Compounds - Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed. | 2013-05-30 |
20130136759 | ANTI-RSV IMMUNOGENS AND METHODS OF IMMUNIZATION - Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof. | 2013-05-30 |
20130136760 | STREPTOCOCCUS PYOGENES ANTIGENS AND CORRESPONDING DNA FRAGMENTS - The present invention relates to antigens, more particularly antigenS of | 2013-05-30 |
20130136761 | S. PNEUMONIAE ANTIGENS - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 2013-05-30 |
20130136762 | MODIFIED SURFACE ANTIGEN - Novel proteins that constitute modified forms of a | 2013-05-30 |
20130136763 | Methods Of Treatment With Compositions That Include Hemagglutinin - Methods that stimulate a protective immune response in a subject include a portion of a protein from a naturally occurring viral hemagglutinin, wherein the protein portion includes at least a portion of a globular head and at least a portion of at least one secondary structure that causes the globular head to essentially retain its tertiary structure, and wherein the protein portion lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. Compositions administered to the subject can further include a carrier and can be administered in single or multiple doses. | 2013-05-30 |
20130136764 | PREPARATION OF CONJUGATES COMPRISING ADENINE DERIVATIVES AND ALLERGENIC PROTEINS AND THEIR USE FOR SPECIFIC IMMUNOTHERAPY OF ALLENGENIC DISEASES - The present invention refers to the preparation of adenine derivative active esters of formula (I) and use thereof for the preparation of stable conjugates between adenine derivative and allergenic proteins having general structure (II) for the modulation of T | 2013-05-30 |
20130136765 | DHEA production-promoting agent and method for producing DHEA production-promoting agent - The present invention aims to provide novel DHEA production promoting agent for anti-aging and improvement of life functions, and applied products that contain the agent. The applied products include foods, food additives, supplements, lotions, cosmetics, etc. The DHEA production promoting agent of the present invention contains an extract of truffles. It is desirable that this extract is at least one of extraction liquids extracted with an organic solvent or hot water. More preferably, it is obtained by extracting the truffles with the organic solvent at the temperature range of | 2013-05-30 |
20130136766 | EFFECTIVE FRACTION FROM THE FRUITING BODIES OF GANODERMA LUCIDUM, EXTRACTION METHOD, USE AND PREPARATION THEREOF - An effective fraction from the fruiting bodies of | 2013-05-30 |
20130136767 | COMPOSITIONS, METHODS AND USES FOR POXVIRUS ELEMENTS IN VACCINE CONSTRUCTS - Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject. | 2013-05-30 |
20130136768 | Recombinant HCMV and RHCMV vectors and uses thereof - Described herein are recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens. The recombinant vectors elicit and maintain high level cellular and humoral immune responses specific for the heterologous antigen. The recombinant RhCMV and HCMV vectors may be used, for example, for the treatment or prevention of infectious disease or cancer. In some examples, the recombinant RhCMV or HCMV vectors may include deletions in genes encoding immunomodulatory proteins. In some examples, the recombinant RhCMV or HCMV vectors may be deficient or impaired in their ability to replicate within a cell, disseminate within the host or spread among hosts by including a deletion in one or more genes essential or augmenting for CMV replication, dissemination or spread. | 2013-05-30 |
20130136769 | NON-DIGESTIBLE OLIGOSACCHARIDES FOR ORAL INDUCTION OF TOLERANCE AGAINST DIETARY PROTEINS - Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins. | 2013-05-30 |
20130136770 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION - Provided herein are methods for modulating immune responses to a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof. Also provided herein are methods for treating, preventing, ameliorating, and/or delaying the onset of one or more symptoms associated with or resulting from a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof. | 2013-05-30 |
20130136771 | OLIGODEOXYNUCLEOTIDE AND ITS USE TO INDUCE AN IMMUNE RESPONSE - A substantially pure or isolated oligodeoxynucleotide of at least 10 nucleotides is disclosed, wherein the oligodeoxynucleotide comprised a sequence represented by either formula: | 2013-05-30 |
20130136772 | REGULATION OF IMMUNE RESPONSE BY COLOCYNTHIN AND/OR ITS DERIVATIVES - The present invention relates to a method of inhibiting pro-inflammatory and T-cell mediated cytokines, said method comprising step of administering to a subject in need thereof a therapeutically effective amount of colocynthin and/or its derivatives. The invention also relates to a method of inhibiting T-cell surface markers and to a method of regulating immune response by colocynthin and/or its derivatives. | 2013-05-30 |
20130136773 | Expandable Placental Membrane and Methods of Making and Storing Same - A placental membrane including a plurality of slits for increasing the membrane's capacity to expand. The slits are provided through the membrane and provided in sufficient numbers across the surfaces of the membrane to produce a mesh-like pattern in the membrane. The mesh-like pattern enables the placental membrane to be stretched and therefore increased in length and width. For ease of handling and storage, the expandable placental membrane is removably adhered to a backing, rolled into a cylinder and placed within a capped vial containing a solution of amniotic fluid cells for improving the effectiveness of the membrane. | 2013-05-30 |
20130136774 | POLYMERIC DRUG-DELIVERY MATERIAL, METHOD FOR MANUFACTURING THEREOF AND METHOD FOR DELIVERY OF A DRUG-DELIVERY COMPOSITION - A method for manufacturing a drug-delivery composition includes providing at least one pharmaceutically active compound, a dry powder comprising at least a polymer, and an aqueous solution. The dry powder, the pharmaceutically active compound and the aqueous solution are mixed to form a paste-like or semi-solid drug-delivery composition, wherein the aqueous solution is added in an amount of less than or equal to twice the total dry mass of the dry powder. | 2013-05-30 |
20130136775 | HYDROPHOBIC DRUG-DELIVERY MATERIAL, METHOD FOR MANUFACTURING THEREOF AND METHODS FOR DELIVERY OF A DRUG-DELIVERY COMPOSITION - A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition. | 2013-05-30 |
20130136776 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C VIRUS - Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period. | 2013-05-30 |
20130136777 | Bone Matrix Compositions and Methods - Osteoinductive compositions and implants having increased biological activities, and methods for their production, are provided. The biological activities that may be increased include, but are not limited to, bone forming; bone healing; osteoinductive activity, osteogenic activity, chondrogenic activity, wound healing activity, neurogenic activity, contraction-inducing activity, mitosis-inducing activity, differentiation-inducing activity, chemotactic activity, angiogenic or vasculogenic activity, and exocytosis or endocytosis-inducing activity. In one embodiment, a method for producing an osteoinductive composition comprises providing partially demineralized bone, treating the partially demineralized bone to disrupt the collagen structure of the bone, and optionally providing a tissue-derived extract and adding the tissue-derived extract to the partially demineralized bone. In another embodiment, an implantable osteoinductive and osteoconductive composition comprises partially demineralized bone, wherein the collagen structure of the bone has been disrupted, and, optionally, a tissue-derived extract. | 2013-05-30 |
20130136778 | PTEROSTILBENE (PTER) FOR USE IN THE PREVENTION AND/OR TREATMENT OF SKIN DISEASES, DAMAGES OR INJURIES - The present invention refers to the use of PTER, or any acceptable salt thereof, optionally in combination with QUER, or any acceptable salt thereof, for the manufacture of pharmaceutical compositions for preventing and/or treating skin diseases, damages or injuries. Those methods of prevention and/or treatment comprise the administration of an effective amount of a composition comprising PTER as active compound, or any acceptable salt thereof, optionally in combination with QUER, or any acceptable salt thereof, to the subject. The present invention also refers to the compositions, per se, comprising PTER as active compound, or any acceptable salt thereof, optionally in combination with QUER, or any acceptable slat thereof, characterized by being formulated in the form of liposomes, and to the method for preparing said liposome formulations. | 2013-05-30 |
20130136779 | METHOD OF PRODUCING NANO- AND MICROCAPSULES OF SPIDER SILK PROTEIN - The present invention is directed to a method of producing nano- and microcapsules from spider silk proteins The invention is further directed to nano- or microcapsules obtainable by this method as well as pharmaceutical, cosmetical and food compositions containing same. | 2013-05-30 |
20130136780 | CROSSLINKED POLYSACCHARIDE GEL COMPOSITIONS FOR MEDICAL AND COSMETIC APPLICATIONS - Methods of producing a biocompatible polysaccharide gel composition having sustained release properties are disclosed. Also disclosed is a biocompatible polysaccharide gel composition having sustained release properties, a method of treating a disease or condition using the present biocompatible polysaccharide gel composition, and a method of controlling rate of release of at least one target solute from the biocompatible polysaccharide gel composition. Pharmaceutical compositions which include the present biocompatible polysaccharide gel composition also are disclosed. | 2013-05-30 |
20130136781 | REINFORCED ABSORBABLE MULTILAYERED HEMOSTATIC WOUND DRESSING - The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen. | 2013-05-30 |
20130136782 | Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives - Compounds described herein inhibit biofilm formation or disperse pre-formed biofilms of Gram-negative bacteria. Biofilm-inhibitory compounds can be encapsulated or contained in a polymer matrix for controlled release. Coatings, films, multilayer films, hydrogels, microspheres and nanospheres as well as pharmaceutical compositions and disinfecting compositions containing biofilm-inhibitory compounds are also provided. Methods for inhibiting formation of biofilms or dispersing already formed biofilms are provided. Methods for treating infections of gram-negative bacteria which form biofilms, particularly those of | 2013-05-30 |
20130136783 | HYDROPHILIZED ANTIMICROBIAL POLYMERS - A bactericidal or antimicrobial polymeric composition includes a hydrophilic first comonomer copolymerized to a second comonomer to produce a polymeric composition that is more hydrophilic or more bactericidal or antimicrobial in an aqueous solution than either of the comonomers alone. Methods for identifying bactericidal or antimicrobial polymers, methods for rendering materials bactericidal or antimicrobial, and methods for using bactericidal or antimicrobial compositions to kill or reduce bacterial or microbial growth are also described. Applications for the inventive compositions include their use in catheters, stents, medical devices, contact lenses; root canal fillers; fibers; paper; and/or wound dressing. | 2013-05-30 |
20130136784 | METHODS FOR DELIVERY OF MEDICATION USING DISSOLVABLE DEVICES - A method utilizing a dissolvable device for the internal delivery of medication and more particularly to the use of fibers or non-woven fabrics made of a safe polymer material incorporating a medication that is released by dissolution of the fibers or non-woven fabrics over time, and more particularly a treatment method for controlling or regulating the pH in the vagina by stabilizing and adjusting the pH in the vagina by minimizing the impact of the vaginal flora. | 2013-05-30 |
20130136785 | ACTIVE SUBSTANCE-RELEASING WOUND DRESSING - The invention relates to a wound dressing, comprising a liquid-absorbing substrate having active substance depots contained therein, wherein the active substance depots comprise particles of at least one active substance which are encapsulated in a silicone shell. The invention further relates to a wound dressing according to the invention for use as a means for treating wounds and to the use of a wound dressing according to the invention for producing a means for treating wounds. | 2013-05-30 |
20130136786 | LONG NON-CODING RNA SPRY4-IT1 AS A DIAGNOSTIC AND THERAPEUTIC AGENT - Provided herein are methods for the diagnosis of cancer by comparison of a quantification of long non-coding RNA SPRY4-IT1 with the same measurement taken in a reference sample from a healthy patient. Further provided herein are methods of anticipating the likelihood that such a disease will develop, and methods of treatment in the event of such development. | 2013-05-30 |
20130136787 | Liposomal Camptothecins and Uses Thereof - This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis. | 2013-05-30 |
20130136788 | METHOD FOR TREATING PULMONARY DISORDERS WITH LIPOSOMAL AMIKACIN FORMULATIONS - Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period. | 2013-05-30 |
20130136789 | AGENT FOR TREATING RENAL FIBROSIS - The present invention relates to a substance delivery carrier for extracellular matrix-producing cells in the kidney, the carrier including a retinoid as a targeting agent, an agent for treating renal fibrosis utilizing the carrier, a process for producing them, a production kit, a method for treating renal fibrosis using the agent for treating renal fibrosis, etc. | 2013-05-30 |
20130136790 | LIPOSOMES WITH IMPROVED DRUG RETENTION FOR TREATMENT OF CANCER - The present invention relates to the use of copper ions to achieve enhanced retention of a therapeutic agent within a liposome. The invention may be employed to more effectively deliver a liposomally encapsulated therapeutic agent to a target site in vitro and in vivo for anti-cancer or other therapy. The liposome may comprise an interior buffer solution containing the therapeutic agent, the solution having a pH less than 6.5 and most preferably approximating pH 3.5. At least some of the copper ions are retained within the interior solution. In a particular embodiment the therapeutic agent may be a chemotherapeutic drug, such as irinotecan. The invention may also comprise an ionophore to facilitate loading of drug into the liposome. In one particular embodiment the combination of the ionophore A23187 and encapsulated divalent copper (Cu2+) resulted in an irinotecan formulation that exhibited surprisingly improved drug retention attributes. | 2013-05-30 |
20130136791 | MULTI-PHASE, MULT-COMPARTMENT CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING SAME - A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber. | 2013-05-30 |
20130136792 | MULTI PHASE SOFT GEL CAPSULES, APPARATUS AND METHOD THEREOF - A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form and at least one liquid fill phase. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. Method and apparatus for manufacturing the multiphase soft gelatin dosage forms are also described. The solid phase, liquid phase or coatings may comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, therapeutic substances, functional excipients or combinations thereof. | 2013-05-30 |
20130136793 | High Content Sodium Ibuprofen Granules, Their Preparation and Their Use in Preparing Non-Effervescent Solid Dosage Forms - Disclosed is a method for the preparation of easily-swallowed, reliably-dosed, aesthetically-improved tablets of sodium ibuprofen dihydrate, the method comprising the formation of the tablets with punches or presses comprising contact surfaces which are chrome or chrome-plated. | 2013-05-30 |
20130136794 | HETEROARYL (ALKYL) DITHIOCARBAMATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF - Heteroaryl(alkyl)dithiocarbamate compounds represented by general formula (I) or their pharmaceutically acceptable salts, their preparing methods, and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is defined as in the description. The compounds are new tyrosine kinase inhibitors useful as an anti-tumor agents, preferably useful in the preparation of medicines for treating breast cancer, liver cancer, non-small cell lung cancer, gastric cancer, colon cancer, leukaemia or nasal cancer. | 2013-05-30 |
20130136795 | SOLID VALSARTAN COMPOSITION - The present invention relates to stable solid pharmaceutical compositions comprising valsartan as the active pharmaceutical ingredient. Optionally the compositions comprise one or more further active pharmaceutical ingredients. The invention further relates to methods for preparing said compositions and to the use of said compositions in the treatment or prevention of angiotensin receptor mediated disorders, in particular hypertension and related disorders. | 2013-05-30 |
20130136796 | Acellular Bioabsorbable Tissue Regeneration Matrices - The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration of damaged, lost and/or degenerated tissue. In certain embodiments, methods and compositions of the present invention are useful in the treatment of damaged, lost and/or degenerated nerve tissue. | 2013-05-30 |
20130136797 | Modified Release Formulations Containing Drug-Ion Exchange Resin Complexes - An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making the coated complex and the liquid suspension are described. | 2013-05-30 |
20130136798 | NOVEL PARENTERAL CONTROLLED RELEASE FORMULATIONS OF NSAID'S - A controlled release parenteral formulation for treatment of pain and inflammation is provided. The formulation includes an effective amount of: one or more active drug moiety. The drug moiety is selected from a group comprising aceclofenac or diclofenac or a combination thereof; One or more solvent moiety selected from a group comprising one or more of ethyl acetate, triacetin, di methyl iso sorbide, DMA, DMSO, PEG, PVP, PVA, Span 80, DCM, Benzyl alcohol, acetone or a combination thereof. The formulation, upon administration, has a release profile including an immediate burst release and the burst release is followed by a slow release of at least 18 to 24 hrs. The immediate burst release and the slow release of the drug moiety remains within the therapeutic window of the drug moiety. | 2013-05-30 |
20130136799 | MONITORING HEALTH AND DISEASE STATUS USING CLONOTYPE PROFILES - There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers. | 2013-05-30 |
20130136800 | Enteral Or Oral Food Product Intended, In Particular, For nutrition And For The Prevention And Improvement Of Neurological Alterations, Neurodegenerative Alterations or Cognitive Disorders - The present invention relates to a complete food product for specific nutritional use, especially intended for enteral or oral nutrition of patients who suffer neurological or neurodegenerative alterations, and for the prevention of cognitive or behaviour disorders, especially in the case of elderly persons, such food product comprising a functional ingredient especially conceived for the nourishment of patients suffering from, or prone to neurological or neurodegenerative alterations, cognitive deterioration or behaviour disorders, as well as a mixture of carbohydrates, a mixture of proteins, a mixture of lipids and dietary fibre, inulin, vitamins and minerals. | 2013-05-30 |
20130136801 | Antimicrobial Composition Including a Residual Barrier Film - This disclosure describes example antimicrobial compositions that may be used in combination with IV port cleansing caps, protective caps, or nasal decolonizer devices. According to another implementations, the disclosure describes that the antimicrobial composition may provide an indication that it has come into contact with a contaminant by bubbling or foam on a surface that is being cleaned. According to another implementation, the disclosure describes that the antimicrobial composition may leave a residual film or barrier to inhibit the recontamination of a surface that has been cleaned. | 2013-05-30 |
20130136803 | COMPOSITIONS FOR ALGAE TREATMENT IN RECIRCULATING AND STAGNANT WATER SYSTEMS - The present invention provides a composition for treating recirculating or stagnant water. The composition contains a phosphorus-containing compound, which is metaphosphate compound, a polyphosphoric acid or a polyphosphate, and one or more zinc compounds. The phosphorus-containing compound is a compound which is not readily hydrolyzable to an orthophosphate. | 2013-05-30 |
20130136804 | Crystal Forms of Kinase Inhibitors - N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer. | 2013-05-30 |
20130136805 | FOAMABLE COMPOSITIONS OF STABILIZED CHLORITE - The present application relates to foamable compositions and foams comprising stabilized chlorite, including stabilized chlorite solutions such as Oxovasin™, and to medical uses thereof, in particular for wound healing. The foamable compositions comprise at least one foaming agent, stabilized chlorite, water and optionally, a buffering agent. | 2013-05-30 |
20130136806 | COMPOSITIONS FOR BOWEL CLEANSING AND USE THEREOF - The present invention relates to a dry composition for reconstitution in water comprising polyethylene glycol (PEG), optionally sodium sulphate, citric acid, sodium citrate, sodium chloride, potassium chloride, simethicone, effective for bowel cleansing, in particular of colon, prior to diagnostic, surgical or therapeutical procedures, in particular colonoscopy. | 2013-05-30 |
20130136807 | INSECT PROOF AND INSECTICIDAL COMPOSITION FOR THE CONSERVATION OF CULTURAL PROPERTY COMPRISING Asarum sieboldii EXTRACT OR A FRACTION THEREOF AS AN ACTIVE INGREDIENT - Disclosed herein is an insect proof or insecticidal composition for the conservation of cultural properties against termites, comprising an extract of | 2013-05-30 |
20130136808 | PLANT-DERIVED FORMULATIONS FOR TREATMENT OF HIV - Disclosed herein are methods for treating mammals with HIV/AIDS comprising administering a therapeutically effective amount of a composition comprising an extract of | 2013-05-30 |
20130136809 | 7-HYRDROXYFRULLANOLIDE ITS ANALOGS FOR PREVENTION CONTROL AND TREATMENT OF METABOLIC DISORDERS - The invention discloses biologically active ingredient(s) selected from 7-hydroxyfrullanolide, its analogs, the ex-tract(s) and fraction(s) standardized to 7-hydroxyfrullanolide or its analogs or both or mixtures thereof or their composition(s) for the prevention, control and treatment of one or more obesity, overweight, metabolic syndrome, diabetes and other metabolic disorders or for producing lean body mass in a warm blooded animal in need thereof. | 2013-05-30 |
20130136810 | COMPOSITIONS AND METHODS FOR PROMOTING WEIGHT LOSS AND INCREASING ENERGY - The present invention relates to compositions comprising plants and extracts of plants with chlorogenic acids and antioxidants and/or caffeine; methods for preparing the same; and methods to promote weight loss through the administration of compositions containing these plants and plant extracts in specific proportions. | 2013-05-30 |
20130136811 | Compositions and Methods for Pain Reduction - Compositions containing four-herb extract combination or Wogonin are useful in methods for the reduction of pain. A four-herb combination is used to treat pain as well as reduce or prevent epileptic seizures. | 2013-05-30 |
20130136812 | ALCOHOL EXTRACT OF DEHULLED ADLAY SEEDS FOR TREATING GASTRIC ULCER AND/OR STOMACH CANCER - The present invention provides a method for treating gastric ulcer and/or stomach cancer in a subject, which comprises administering to said subject an effective amount of an alcohol extract of dehulled adlay seeds. Preferably, an ethyl acetate sub-fraction of the alcohol extract of dehulled adlay seeds has a better effect in treating gastric ulcer and/or stomach cancer. | 2013-05-30 |
20130136813 | ANTI-INFLAMMATORY COMPOSITIONS - The present invention relates to the use as an anti-inflammatory of tamarind seed polysaccharide (TSP) and to anti-inflammatory compositions which contain it as active ingredient. Anti-inflammatory compositions containing TSP are particularly useful for topical administration in the treatment of inflammatory diseases of the skin and mucosa. | 2013-05-30 |
20130136814 | PREPARATION FOR WEIGHT LOSS MANAGEMENT - extracts together with extracts of one or more of | 2013-05-30 |
20130136815 | INSECT-REPELLENT OR INSECTICIDAL COMPOSITION COMPRISING EXTRACT OR FRACTION OF OAK VINEGAR AS AN EFFECTIVE INGREDIENT FOR CONSERVATION OF CULTURAL HERITAGE - An insect-repellent or insecticidal composition comprising an extract or an organic solvent fraction of oak vinegar as an effective ingredient, is provided. The composition comprising extract or organic solvent fraction of oak vinegar as an effective ingredient has superior insect-repellent or insecticidal activities against | 2013-05-30 |
20130136816 | APPARATUS FOR NON-DESTRUCTIVELY INSPECTING A CONVEYOR BELT DURING MANUFACTURE THEREOF UTILIZING HIGH-ENERGY RAYS - An apparatus non-destructively inspects a conveyor belt in a production facility. The conveyor belt defines a belt surface and has cover plates made of a rubber mixture. The production facility includes a vulcanizing press for vulcanizing the conveyor belt during production thereof. The apparatus includes a housing forward or rearward of the press. The housing has openings through which the conveyor belt passes. A radiation source mounted in the housing transmits rays toward the belt surface and the radiation source is configured to transmit the rays with energy sufficient to cause the rays to pass through the conveyor belt. A sensor mounted in the housing detects the rays passed through the conveyor belt to facilitate a radiographic check by providing actual values of the conveyor belt. A processor evaluates the radiographic check by comparing the actual values of the conveyor belt to set values of the conveyor belt. | 2013-05-30 |
20130136817 | TEMPERATURE ADJUSTING DEVICE, AND IMPRINTING DEVICE USING SAME - A temperature adjusting device that can heat and cool an object like a mold or a molding target uniformly and quickly, and an imprinting device using the same are provided. The temperature adjusting device is for adjusting a temperature of the object like a mold | 2013-05-30 |
20130136818 | Resin Mold for Nanoimprinting - Disclosed is a resin mold for nanoimprinting, which has a resin layer having fine depressions and protrusions formed on the surface and is characterized in that the resin layer is formed from 1 to 49 parts by weight of a silicone-based macromonomer and/or a fluorine-based macromonomer and 99 to 51 parts by weight of at least one polymerizable monomer selected from the group consisting of a (meth)acrylic monomer, a styrene-based monomer, an epoxy-based monomer, an olefin-based monomer and a polycarbonate-based resin-forming monomer, the silicone-based macromonomer and/or the fluorine-based macromonomer has a molecular weight of 600 to 10000 and has, at an end of molecule, a reactive group copolymerizable with the polymerizable monomer, and when the reactive group is copolymerized with the polymerizable group, silicone-based units or fluorine-based units that constitute the macromonomer form side chains on a trunk polymer formed from the polymerizable monomer and the macromonomer. | 2013-05-30 |
20130136819 | PRESS FOR VACUUM VIBRO-COMPRESSION OF SLABS OR BLOCKS OR ARTICLES OF AGGLOMERATED OR CERAMIC MATERIAL - A press for vacuum vibro-compression of slabs or blocks or articles of agglomerated or ceramic material comprises a ram with a pressing surface provided with means for generating a vibratory movement, which comprise a first and a second set of vibrating devices, each device being provided with at least one rotating shaft with an eccentric mass. The shafts of the vibrating devices of one set rotate in the opposite direction to the shafts of the vibrating devices of the other set. Each set comprises at least two vibrating devices which are arranged with their respective axes not coaxial and interconnected by kinematic connection means for rotating in synchronism. | 2013-05-30 |
20130136820 | APPARATUS FOR PROCESSING SCRAP CROSS-LINKED THERMOSET ELASTOMERIC MATERIAL - An apparatus for processing thermoset cross-linked elastomeric scrap material has a batch-operated high shear mixer for inducing chemical reactions to partly devulcanize the material in a first devulcanizing stage. A continuously-operated multi-screw cooled extruder receives the partly devulcanized material from the high shear mixer and further devulcanizes the material by a mechanical shearing action in a second stage to produce an extruded product for revulcanization. | 2013-05-30 |